10-K: BioForce Nanosciences Holdings Reports Zero Revenue for 2023, Faces Going Concern Uncertainty

BioForce Nanosciences Holdings reported no revenue for the fiscal year 2023 and faces substantial doubt about its ability to continue as a going concern.

Summary

• BioForce Nanosciences Holdings, Inc. reported zero revenue for the fiscal years ending December 31, 2023 and 2022.
• The company's mission is to become a leading provider of natural vitamins, minerals, and nutritional supplements.
• BioForce had no unit sales of its BioForce Eclipse supplement product in 2023 or 2022.
• The company's net loss for 2023 was $471,953, a slight decrease from the $485,514 loss in 2022.
• As of December 31, 2023, BioForce had total assets of $638 and total liabilities of $1,819,868, resulting in a working capital deficit of $1,819,230.
• The company has an accumulated deficit of $160,629,729 as of December 31, 2023.
• BioForce is dependent on additional debt and equity financing to continue operations.
• Management intends to raise additional funds through an offering of debt or equity securities.
• The company's internal controls over financial reporting were deemed ineffective as of December 31, 2023, due to inadequate segregation of duties and a lack of review in the financial reporting process.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to zero revenue, significant losses, and a going concern warning. The company's financial position is precarious, and its future is highly uncertain.

Positives

• The company's net loss decreased slightly from 2022 to 2023.
• The company has an oral commitment from its Chairman to provide funding for the next 12 months.
• BioForce is actively seeking to expand its marketing efforts and product reach.

Negatives

• BioForce reported zero revenue for both 2023 and 2022.
• The company has a significant accumulated deficit of $160,629,729.
• The company's liabilities significantly outweigh its assets.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's internal controls over financial reporting are ineffective.
• BioForce has not paid any dividends and does not anticipate paying any in the foreseeable future.

Risks

• The company's reliance on third parties for technology and manufacturing poses a risk.
• The company faces intense competition in the nutritional supplement market.
• The company's ability to raise additional capital is uncertain.
• The company's dependence on key employees is a risk.
• The company's lack of profitability and significant operating losses raise concerns about its long-term viability.
• The company's internal control deficiencies could lead to material misstatements in financial reporting.
• The company has no customers and is dependent on attracting new customers.

Future Outlook

The company plans to expand its marketing efforts, including direct marketing, B2B sales, and online channels, to increase brand awareness and drive sales of its nutritional supplements. The company also intends to explore new product lines and markets.

Management Comments

• Management believes that the actions presently being taken to further implement our business plan and generate revenues provide the opportunity for BioForce to continue as a going concern.
• Management intends to raise additional funds by way of an offering of our debt or equity securities.

Industry Context

The company operates in the approximately $36 billion vitamin and supplement manufacturing industry, which grows on average 2.5% annually. The industry is competitive, with several established players, but BioForce aims to differentiate itself through product quality and convenient retail channels.

Comparison to Industry Standards

• The company's lack of revenue is significantly below industry standards for established companies in the nutritional supplement sector.
• Many competitors in the vitamin and supplement industry have established distribution networks and brand recognition, which BioForce currently lacks.
• Companies like GNC, Vitamin Shoppe, and large pharmaceutical companies have significant revenue streams and established market presence, which BioForce is attempting to compete with.
• The company's financial position is significantly weaker than industry benchmarks, with a substantial accumulated deficit and negative working capital.

Management Changes

Corporate Governance

Related Party Transactions

• Mr. Merle Ferguson, the company's Chairman, paid $43,568 of the company's expenses in 2023 and $54,315 in 2022.
• Mr. Richard Kaiser, the company's CFO and Director, paid $3,038 of the company's expenses in 2023 and $3,602 in 2022.
• The company owes $220,702 to related parties as of December 31, 2023.

Stakeholder Impact

• Shareholders face significant risk due to the company's poor financial performance and going concern uncertainty.
• Employees may be impacted by potential restructuring or cessation of operations.
• Customers are not currently impacted as the company has no sales, but future customers may be affected by the company's ability to deliver products.
• Suppliers and creditors face risk of non-payment due to the company's financial instability.

Next Steps

• The company plans to expand its marketing efforts with a direct marketing and B2B sales campaign.
• The company will approach retail stores to create vendor relationships.
• The company will continue to advance its social media platform with direct online and targeted advertisements.
• The company will evaluate the success of its marketing objectives and determine which marketing strategy provides the best results.
• The company intends to market a new biodegradable, recyclable container of its products.
• The company will evaluate potential new product lines.

Key Dates

Keywords

nutritional supplements, vitamins, minerals, dietary supplements, going concern, financial reporting, internal controls, revenue, net loss, debt financing, equity financing, marketing, BioForce Eclipse